ophthalmology

News

Aldeyra spies FDA filing ahead for dry eye drug reproxalap

Aldeyra Therapeutics' dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off.

News

SparingVision raises €75m for eye disease gene therapies

SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related ma

News

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseas...

A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product.

News

Alcon eyes $770m takeover of ophthalmology specialist Aerie

Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25 per share offer to buy Aerie Pharmaceuticals in a transaction that values the U

News

Roche's fast-growing eye drug Vabysmo set for EU approval

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its

Events